|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
47,500,000 |
Market
Cap: |
2.01(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$38.65 - $65 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Amphastar Pharmaceuticals is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing and selling generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient (API) products. Co.'s reportable segments are: finished pharmaceutical products, which manufactures, markets and distributes Primatene Mist®, glucagon, enoxaparin, naloxone, phytonadione, lidocaine, epinephrine, various critical and non-critical care drugs; and API, which manufactures and distributes recombinant human insulin API and porcine insulin API for external customers and internal product development.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
31,636 |
387,836 |
590,546 |
794,601 |
Total Sell Value |
$1,475,158 |
$21,735,076 |
$32,576,849 |
$40,646,784 |
Total People Sold |
3 |
5 |
8 |
10 |
Total Sell Transactions |
4 |
11 |
26 |
62 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Prins Richard K |
Director |
|
2018-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
6,590 |
35,434 |
|
- |
|
Petersen Floyd F. |
Director |
|
2018-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
6,590 |
71,151 |
|
- |
|
Luo Mary Z. |
COO,Chief Scientist & Chairman |
|
2018-05-16 |
4 |
B |
$16.06 |
$240,854 |
D/D |
15,000 |
2,080,619 |
3.23 |
- |
|
Luo Mary Z. |
COO,Chief Scientist & Chairman |
|
2018-05-15 |
4 |
B |
$16.08 |
$401,970 |
D/D |
25,000 |
2,065,619 |
3.23 |
- |
|
Peters William J |
CFO, SVP & Treasurer |
|
2018-04-21 |
4 |
D |
$19.31 |
$24,582 |
D/D |
(1,273) |
91,374 |
|
- |
|
Shandell Jason B. |
President and General Counsel |
|
2018-03-27 |
4 |
D |
$18.47 |
$144,676 |
D/D |
(7,833) |
212,561 |
|
- |
|
Peters William J |
CFO, SVP & Treasurer |
|
2018-03-26 |
4 |
D |
$18.61 |
$31,209 |
D/D |
(1,677) |
92,647 |
|
- |
|
Shandell Jason B. |
President and General Counsel |
|
2018-03-26 |
4 |
D |
$18.61 |
$83,596 |
D/D |
(4,492) |
220,394 |
|
- |
|
Luo Mary Z. |
COO Chief Scientist & Chairman |
|
2018-03-26 |
4 |
D |
$18.61 |
$164,587 |
I/I |
(8,844) |
1,346,129 |
|
- |
|
Luo Mary Z. |
COO Chief Scientist & Chairman |
|
2018-03-26 |
4 |
D |
$18.61 |
$385,748 |
D/D |
(20,728) |
2,040,619 |
|
- |
|
Zhou Rong |
EVP, Production Center |
|
2018-03-26 |
4 |
D |
$18.61 |
$9,956 |
D/D |
(535) |
54,434 |
|
- |
|
Shandell Jason B. |
President and General Counsel |
|
2018-03-20 |
4 |
AS |
$19.52 |
$161,871 |
D/D |
(8,293) |
224,886 |
|
- |
|
Shandell Jason B. |
President and General Counsel |
|
2018-03-19 |
4 |
AS |
$19.37 |
$226,767 |
D/D |
(11,707) |
233,179 |
|
- |
|
Shandell Jason B. |
President and General Counsel |
|
2018-03-17 |
4 |
D |
$19.91 |
$129,136 |
D/D |
(6,486) |
244,886 |
|
- |
|
Peters William J |
CFO, SVP & Treasurer |
|
2018-03-17 |
4 |
D |
$19.91 |
$68,371 |
D/D |
(3,434) |
94,324 |
|
- |
|
Luo Mary Z. |
COO, Chief Scientist, Chairman |
|
2018-03-17 |
4 |
D |
$19.91 |
$190,917 |
I/I |
(9,589) |
1,354,973 |
|
- |
|
Luo Mary Z. |
COO, Chief Scientist, Chairman |
|
2018-03-17 |
4 |
D |
$19.91 |
$606,996 |
D/D |
(30,487) |
2,061,347 |
|
- |
|
Zhou Rong |
EVP, Production Center |
|
2018-03-17 |
4 |
D |
$19.91 |
$19,293 |
D/D |
(969) |
54,969 |
|
- |
|
Shandell Jason B. |
President and General Counsel |
|
2018-03-16 |
4 |
D |
$19.91 |
$109,405 |
D/D |
(5,495) |
251,372 |
|
- |
|
Peters William J |
CFO, SVP & Treasurer |
|
2018-03-16 |
4 |
D |
$19.91 |
$58,038 |
D/D |
(2,915) |
97,758 |
|
- |
|
Luo Mary Z. |
COO, Chief Scientist, Chairman |
|
2018-03-16 |
4 |
D |
$19.91 |
$154,721 |
I/I |
(7,771) |
1,364,562 |
|
- |
|
Luo Mary Z. |
COO, Chief Scientist, Chairman |
|
2018-03-16 |
4 |
D |
$19.91 |
$385,458 |
D/D |
(19,360) |
2,091,834 |
|
- |
|
Zhou Rong |
EVP, Production Center |
|
2018-03-16 |
4 |
D |
$19.91 |
$22,458 |
D/D |
(1,128) |
55,938 |
|
- |
|
Zhou Rong |
EVP, Production Center |
|
2018-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
8,969 |
57,066 |
|
- |
|
Luo Mary Z. |
COO, Chief Scientist, Chairman |
|
2018-03-15 |
4 |
A |
$0.00 |
$0 |
I/I |
41,687 |
1,372,333 |
|
- |
|
956 Records found
|
|
Page 24 of 39 |
|
|